The role of liposomes in clinical nanomedicine development. What now? Now what?

Daan J A Crommelin; Peter van Hoogevest; Gert Storm

doi:10.1016/j.jconrel.2019.12.023

The role of liposomes in clinical nanomedicine development. What now? Now what?

Daan J A Crommelin, Peter van Hoogevest, Gert Storm

Phospholipid Research Center Heidelberg, Im Neuenheimer Feld 515, D-69120 Heidelberg, Germany. Electronic address: [email protected].

Research output: Contribution to journal › Review article › peer-review

Abstract

The rapid rise in interest in 'nanomedicines' in the academic world over the last twenty years and the claims of success led to calls for reflection. The main body of text of this Commentary will be on answering the question: 'where to go with nanomedicines'? Research priorities for the future will be outlined based on experience with the most successful nanomedicines family within the broad field of nanomedicine so far: liposomes. An analysis of currently clinically tested, approved and marketed liposome-drug combinations provides these insights.

Original language	English
Pages (from-to)	256-263
Number of pages	8
Journal	Journal of controlled release : official journal of the Controlled Release Society
Volume	318
DOIs	https://doi.org/10.1016/j.jconrel.2019.12.023
Publication status	Published - Feb 2020

Keywords

Liposomes
Nanomedicines
Clinical trials

Access to Document

10.1016/j.jconrel.2019.12.023

1-s2.0-S0168365919307424-mainFinal published version, 688 KBLicence: Taverne

Cite this

@article{606c6f370ada4e508d0f27c66762a462,

title = "The role of liposomes in clinical nanomedicine development. What now? Now what?",

abstract = "The rapid rise in interest in 'nanomedicines' in the academic world over the last twenty years and the claims of success led to calls for reflection. The main body of text of this Commentary will be on answering the question: 'where to go with nanomedicines'? Research priorities for the future will be outlined based on experience with the most successful nanomedicines family within the broad field of nanomedicine so far: liposomes. An analysis of currently clinically tested, approved and marketed liposome-drug combinations provides these insights.",

keywords = "Liposomes, Nanomedicines, Clinical trials",

author = "Crommelin, {Daan J A} and {van Hoogevest}, Peter and Gert Storm",

year = "2020",

month = feb,

doi = "10.1016/j.jconrel.2019.12.023",

language = "English",

volume = "318",

pages = "256--263",

journal = "Journal of controlled release : official journal of the Controlled Release Society",